It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Ductal carcinoma in situ (DCIS) is a non-invasive type of breast cancer with highly variable potential of becoming invasive and affecting mortality. Currently, many patients with DCIS are overtreated due to the lack of specific biomarkers that distinguish low risk lesions from those with a higher risk of progression. In this study, we analyzed 57 pure DCIS and 313 invasive breast cancers (IBC) from different patients. Three levels of genomic data were obtained; gene expression, DNA methylation, and DNA copy number. We performed subtype stratified analyses and identified key differences between DCIS and IBC that suggest subtype specific progression. Prominent differences were found in tumors of the basal-like subtype: Basal-like DCIS were less proliferative and showed a higher degree of differentiation than basal-like IBC. Also, core basal tumors (characterized by high correlation to the basal-like centroid) were not identified amongst DCIS as opposed to IBC. At the copy number level, basal-like DCIS exhibited fewer copy number aberrations compared with basal-like IBC. An intriguing finding through analysis of the methylome was hypermethylation of multiple protocadherin genes in basal-like IBC compared with basal-like DCIS and normal tissue, possibly caused by long range epigenetic silencing. This points to silencing of cell adhesion-related genes specifically in IBC of the basal-like subtype. Our work confirms that subtype stratification is essential when studying progression from DCIS to IBC, and we provide evidence that basal-like DCIS show less aggressive characteristics and question the assumption that basal-like DCIS is a direct precursor of basal-like invasive breast cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Oslo University Hospital, Department of Cancer Genetics, Institute for Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921)
2 Oslo University Hospital, Department of Cancer Genetics, Institute for Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485)
3 Oslo University Hospital, Oslo Centre for Biostatistics and Epidemiology, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485)
4 Oslo University Hospital, Oslo Centre for Biostatistics and Epidemiology, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); University of Oslo, Department of Biostatistics, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921)
5 Norwegian University of Science and Technology (NTNU), Department of Circulation and Medical Imaging, Trondheim, Norway (GRID:grid.5947.f) (ISNI:0000 0001 1516 2393)
6 Oslo University Hospital, Department of Pathology, Division of Laboratory Medicine, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485)
7 University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); Oslo University Hospital, Department of Oncology, Division of Cancer Medicine, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); Oslo University Hospital, Department of Tumor Biology, Institute for Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485)
8 University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); Akershus University Hospital, Department of Oncology, Lørenskog, Norway (GRID:grid.411279.8) (ISNI:0000 0000 9637 455X); Akershus University Hospital, Division of Medicine, Lørenskog, Norway (GRID:grid.411279.8) (ISNI:0000 0000 9637 455X)
9 Østfold Hospital, Østfold, Norway (GRID:grid.55325.34)
10 Cancer Registry of Norway, Oslo, Norway (GRID:grid.418941.1) (ISNI:0000 0001 0727 140X); Oslo and Akershus University College of Applied Sciences, Faculty of Health Science, Oslo, Norway (GRID:grid.412414.6) (ISNI:0000 0000 9151 4445)
11 Akershus University Hospital, Department of Clinical Molecular Biology, Division of Medicine, Lørenskog, Norway (GRID:grid.411279.8) (ISNI:0000 0000 9637 455X); Centre for Cancer Biomarkers CCBIO, Bergen, Norway (GRID:grid.411279.8)
12 University of Oslo, Centre for Cancer Biomedicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); University of Oslo, Department of Computer Science, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921)
13 Oslo University Hospital, Department of Tumor Biology, Institute for Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); University of Tromsø, Department of Pharmacy, Faculty of Health Sciences, Tromsø, Norway (GRID:grid.10919.30) (ISNI:0000000122595234)
14 University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); Oslo University Hospital, Department of Oncology, Division of Cancer Medicine, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485)
15 Oslo University Hospital, Department of Cancer Genetics, Institute for Cancer Research, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); Oslo University Hospital, Department of Pathology, Division of Laboratory Medicine, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485)
16 University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921); Akershus University Hospital, Department of Pathology, Lørenskog, Norway (GRID:grid.411279.8) (ISNI:0000 0000 9637 455X)
17 Oslo University Hospital, Ullevål, Section for Breast and Endocrine Surgery, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485)
18 Vestre Viken Hospital Trust, Breast and Endocrine Surgery, Department of Breast and Endocrine Surgery, Drammen, Norway (GRID:grid.459157.b) (ISNI:0000 0004 0389 7802)
19 Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Applied Research and Technical development, Milan, Italy (GRID:grid.417893.0) (ISNI:0000 0001 0807 2568)
20 CEA-Institut de Biologie Francois Jacob, Laboratory for Epigenetics and Environment, Centre National de Recherche en Génomique Humaine, Evry, France (GRID:grid.417893.0)
21 Uppsala University, Department of Surgical Sciences, Uppsala, Sweden (GRID:grid.8993.b) (ISNI:0000 0004 1936 9457); Uppsala Academic Hospital, Department of Surgery, Uppsala, Sweden (GRID:grid.412354.5) (ISNI:0000 0001 2351 3333)